Journal of Medical and Health Studies
ISSN: 2710-1452
DOI: 10.32996/jmhs
Journal Homepage: www.al-kindipublisher.com/index.php/jmhs

JMHS
AL-KINDI CENTER FOR RESEARCH AND DEVELOPMENT

| RESEARCH ARTICLE

Computational Biotechnology: The "matrix" of Experimental Biology

Ahmed Naeem Naser Anasih
Department of Pharmaceutical Sciences, College of Pharmacy, University of Thi Qar, Nasiriyah, Thi Qar, Iraq
Corresponding Author: Ahmed Naeem Naser Anasih, **E-mail**: ahmednaeem@utq.edu.iq

| ABSTRACT
In Silico studies is gaining popularity in almost all scientific fields of chemistry, molecular biology, physics, etc., and biotechnology is also not left apart. With the great advancement in our computation powers and the invention of supercomputers, biotechnology stepped into a digital phase. This review article tries to bring out these topics with special emphases on in silico drug discovery.In silico drug discovery uses computational approaches in the identification, design, and optimization of possible drug candidates. It applies techniques of molecular modeling, virtual screening, and prediction algorithms as a method of reducing time and cost toward traditional processes of drug discovery. More advanced techniques applied would include molecular docking, pharmacophore modeling as a complement to in silico drug discovery. With high accuracy, these techniques can predict biological activity, toxicity as well as drug-likeness. In other words, the in-silico approach to drug discovery is an invaluable complementary tool to modern pharmaceutical research in innovating new therapies.

| KEYWORDS

In silico drug discovery, Bioinformatics, In silico Biotechnology, computational biology, Computational Biotechnology

| ARTICLE INFORMATION

ACCEPTED: 12 March 2025 **PUBLISHED:** 05 April 2025 **DOI:** 10.32996/jmhs.2024.6.2.6

1. The Birth of Computational Biotechnology.

1.1. Overview

In silico biotechnology involves applying information and communication technologies as adopted and adapted in the scope of digital technologies for innovation in this field of science by simulating, modeling, and analyzing biological systems. The processes can be designed and implemented with the use of biological information combined with computational tools. Scopes of *in silico* biotechnology include various applications such as drug discovery, genetic engineering, and systems biology. Researchers understand the operations of complex biological processes, promoted by bioinformatics, that manage storage, retrieval, analysis, and interpretation of biological data. Fundamentally, *in silico* biotechnology rests on the application of computer-based methods of study on biological phenomena and concepts whose exploration would be very time-consuming and need vast laboratory means. Virtual models of biological systems are created for hypothesizing the outcomes and testing the theories prior to materialization of costly or laborious work which can be that of a cul-de-sac in the majority of cases. The cross-disciplinary fusion between genetics, molecular biology, and computational science is therefore a fundamental step within the life sciences domain. Moreover, *in silico* approaches can meet the high-throughput analysis demands needed today, especially with massive biological data inflows resulting from powerful new experimental techniques, such as next-generation sequencing. These advances demand sophisticated comparative methods and robust data infrastructures capable of scaling up to large dataset management while also assuring access and utility to the researcher community. In addition, advances in *in silico* biotechnology bring moral issues to the fore of any advance in this field: researchers should advance with caution to match possible restrictions put on them through appropriate regulatory frameworks meant to enforce good, responsible use of the new biotechnological developments. It is therefore appropriate to say that *in silico* biotechnology is an essential collaborator of modern-day life sciences research, bridging the gap between

computational technologies and conventional biological investigation. It immensely helps our capacity to probe and control complex biological phenomena with marked effectiveness.[1] and [2].

1.2 Modern Computational Biotechnology

Computational biotechnology is a major aid in culminating our comprehension and exploitation of biological systems. Coupling computational methodologies with conventional research has completely revolutionized biotechnological research and permits researchers to carry out the analysis of a huge amount of experimental data in an efficient manner. New levels of biological discovery of such complexity that earlier generations of scientists could not fathom due to lack of experimental and analytical tools are made possible.
Assuming the role of one of the major players in this vicissitude biological realm, bioinformatics takes on the gauntlet of handling large biological data sets and interpreting them, from genomic sequences to protein interactions. Indeed, with high-throughput technologies, the ability to store and access large volumes of data is invaluable. This capacity speeds up discovery and ensures accuracy in addressing key biological and medical questions.

Computerized biotechnology has an impact on various fields of pharmaceutical research, genetic engineering, and synthetic biology. Computational models help in the simulation of biochemical pathways and cellular responses and, therefore, improve the design of experiments, which will permit the identification of therapeutic targets much faster and with greater treatments efficacy. Another very important strength of this technological convergence is the opening up of access to more sophisticated tools of research that can bring academic institutions closer to industry by sharing databases and platforms. Amidst this big surge of data, bioinformatics is key to converting information into usable knowledge that will bring improvements in health and evidence-based decision-making from sound data analysis [1] and [3].

2. The Role of Computer & software

2.1. Major types of Software

A vast number of special software tools for various applications within the industry has significantly popularized the field of biotechnology. Software tools in bioinformatics are very important for the management and interpretation of complex biological data, researchers are able to collect genomics sequences and structures of proteins data using powerful tools to help in the efficient analysis and visualization of these data. Some of these key tools in bioinformatics include various sequence alignment programs, huge accompanying databases for the storage of enormous data sets, and calculations performed on computational simulating biological functions. Examples are tools such as BLAST, which are good at sequence alignment, and genome browsers like Ensembl and UCSC Genome Browser, which provide easy access to genomic information. Besides, several databases such as UniProt provide extensive information about proteins. Moreover, many modeling software packages are essential in the simulation of biological processes. A scientist can draw models of biochemical networks using Cell Designer with more visual effect. From these systems biology platforms, different types of biological data are integrated and subjected to a comprehensive analysis; visualization of molecular interaction networks is common by tools such as Cytoscape. Computational chemistry software becomes invaluable in drug discovery by predicting interactions between drugs and their targets. During the process of drug development, virtual screening is one stage where most of the software like MOE and Schrodinger are applied using *in silico* algorithms for predicting binding affinities from structural properties of compounds. On top of that, recent developments brought AI into the field of biotechnology. Machine learning frameworks can be applied for predictive modeling in genomics and for the optimization of experimental design in synthetic biology. Such a combination of different types of software streamlines not only research workflows but also scientific inquiries in an accurate and efficient manner within the field of biotechnology research as multidisciplinary research.[1] and [4].

2.2. Functions and possibilities

Biotechnology software carries out a wide variety of functions to greatly enhance and facilitate the work of research and development. Key among these features are the capabilities of data management, analysis, and simulation. These information management systems assist in the organization, storage, and retrieval of enormous biological datasets that come from gene expressions, protein structures, metabolic pathways, and genomic sequences. Advanced bioinformatics tools that are tailor-made for such operations specifically will have to be developed so that from these large datasets, scientists are able to glean intricate details regarding biochemical interactions.Visualization tools are also applied in the interpretation of biological data. These usually come with software packages that mostly contain graphical interfaces through which scientists can visually create images representing molecular structures, experimental results, and biological networks— again very key tools in the formulation of hypotheses and design experiments. Such visualization capabilities are indispensable in understanding the minutest details and complexities of biological systems. Equally important a function is predictive modeling. Many software applications rely on certain inbuilt algorithms that virtually resemble biological processes that predict unknown outcomes based on available data. For example,

there is a clear rising trend in applying machine learning to identify patterns within large datasets, possibly leading to revolutionary strides in developing new drugs or genetically modifying organisms.It is, therefore, an important feature; modern biotechnology software systems are designed to be compatible with existing databases and computational tools. Researchers should be able to run different data sources simultaneously to increase both the depth and quality of their analyses.With the aid of molecular docking and pharmacophore modeling software, the specific contributions of software to the process of drug discovery are well established. Such *in silico* tools provide a view of possible interactions at the molecular level between a drug and its target biomolecules, hence aiding in the prediction of such interactions.Thereby, this can go a long way in shortening the time needed for validation through early stages of drug development by reducing the burden of validation experiments.Ultimately, the importance of user-friendly interfaces is growing, as different groups of researchers with scant connection between them can now use sophisticated computational approaches without extensive training in bioinformatics or computer science [1, 4, 5].

3.*In Silico* Biotechnology: theory and Application

In silico biotechnology refers to the application of computational methods and simulation technologies within biological research. A range of applications are covered, from the modeling of cellular mechanisms to the prediction of experimental outcomes in biology. At the heart of *in silico* biotechnology is the hybridization of bioinformatics and systems biology, realizing the use of large data sets emanating from genomic, transcriptomic, and proteomic studies. Thus, *in silico* models resort to mathematical frameworks in the simulation of biological interactions at various levels of complexity, from large molecular networks to even larger population dynamics. These are very important functions in hypothesis testing because it is through them that a simulated setting is created where various scenarios can be explored without the ethical or resources problems presented by everyday laboratory experiments. Being able to view complicated biological systems by computational means assists in the revelation of putative drug targets, understanding how diseases work, and coming up with better approaches for real experiments. An overwhelming amount of biological data begun to be generated, following recent advances in high-throughput technologies, far beyond the power of human processing, has underscored the urgent need for developing more sophisticated analytical tools for data management and interpretation. At that point, bioinformatics takes its place in eliminating this gap, as it represents methodologies of pattern recognition and machine learning algorithms of such information and statistical models, greatly improving *in silico* representations. Apart from that, *in silico* methodologies support and complement traditional experimental methodologies by suggesting informative leads on laboratory work; they allow the researchers to scope their hypotheses further so that they do not waste resources on physical experiments. This interplay between computational models and empirical research is central to the progression in understanding complex biological systems[1].

Considering this, *in silico* biotechnology would qualify to be a framework for the investigation of complex biological processes. In the practice of building molecular networks, with these networks modeling becomes highly applicable to give scientists the opportunity to simulate cellular behaviors and evaluate alterations in biomolecules that would support hypothesis testing concerning the control of genes and the dynamics of pathways, which traditional methodologies might overlook. It goes further to integrate such computational tools with diverse biological experiments high-throughput data in exposing details concerning cellular responses in varying environments. The bioinformatics platforms help in the realization of meaningful patterns inside enormous data spaces resulting from omics research, where the understanding of the mechanism of a disease is facilitated, along with the potential detection of biomarkers for clinical use. Apart from that, in systems biology, the computational framework can very much be used to research further into the causes of a disease; thus, the simulation of cellular crosstalk is an upgrade when trying to grasp phenomena from the regulation of the cell cycle to various metabolic pathways. These models not only complement the experimental data, which has been available, but also make it possible to plan new experiments using predictions of various variants of their outcomes; and one of the spheres of scientific research that actively uses such an approach is predictive modeling in drug discovery [1, 6].

4. *In Silico* Drug Discovery

4.1. Stages of Drug Discovery

Drug discovery is very much a multi-disciplinary process but one designed to maximize the chances of eventually developing new and effective therapies. Beginning with target identification, scientists have delved into the biological underpinnings of diseases in search of appropriate molecular targets upon which to focus their search for pharmacological intervention. Having identified these targets, the scientists moved onto hit identification employing either high-throughput screening of compound libraries or via *in silico* methods to find potential candidates in interacting with the identified target. This was followed by lead optimization where the focus is on the potency and specificity of these compounds. Often in this stage, structure-activity relationships (SAR) are evaluated with the aid of computational methods, predicting how a change in chemical structure might affect biological activity. Tools like molecular docking and quantitative structure-activity relationship (QSAR) modeling come in handy in efficiently streamlining the lead compound optimization process. Leads, following optimization, are taken to pre-clinical testing that includes pharmacokinetics, toxicity, and efficacy testing both in vitro and in vivo. At this stage, computational predictions are integrated so

that one can have the faintest idea of the possible pathways and, specifically, any toxicological effects at very early points of development. Candidates that surge even after detailed scrutiny at the preclinical stages are then taken forward for clinical trials. Human clinical trials traditionally come in three phases. Phase I deals with the safety and dosage aspects; Phase II covers effectiveness, and Phase III is comparative testing against existing treatments. The whole process is completed with a regulatory agency review before any new medicine is marketed. Now, it is the application of machine learning and AI-enriched methodologies in these steps that has brought a qualitative increase in productivity and success rates. These innovations allow for more accurate predictions regarding drug behavior, shorten development timelines, and lower costs compared with traditional trial methods [4], [8], and [9].

4.2. Success Stories

The intersection of computational technologies with a landscape littered with as many failure stories as successes has ushered in a remarkable new era for drug discovery. A case in point is INS018_055, poised to become the first artificial intelligence-discovered and developed drug ever. Efficacious in preclinical testing, this TNIK inhibitor has made way into Phase 2 clinical trials. Introduced multicomponent generative AI enables the newly designed small molecules to focus on their synthetic feasibility novelty, and biological activity. This already proves how much artificial intelligence can cut these timelines which are normally referred to in the context of traditional drug discovery. Over the last few years, Atomic Molecular Dynamic Simulations have played yet another very important role in the developments. This has allowed the prediction of binding sites that are novel, and also the binding affinities that are more accurate than what any standard methodology could help in. Computational power and algorithmic development have facilitated the acceptance of MD simulations in pharmaceutical science to streamline the processes of lead identification and optimization. What is more, is that there has been a revolutionary change in the approaches to target discovery efforts through the application of machine learning techniques. That is because eminently large datasets obtained from genetic and clinical research are topics under perfect considerations of AI, disclosing new drug targets while also being able to provide predictive functional characteristics of putative compounds—an impossibility with good possibilities to do through the old methods. These front-line investigators have played a critical role in moving this evolution forward, granting the power of AI to speed up the discovery of drugs-most importantly at institutions such as the University of Alabama at Birmingham. Moreover, initiatives such as the FDA Modernization Act are a paradigm shift towards integrating *in silico* tools into regulatory practices. In fact, more than 20 AI-designed drug candidates are now in the clinic—a marked increase from only a few years ago—attesting to the capacity of AI-driven approaches to improve effectiveness and lower associated costs of bringing new therapies to market launch [7, 10, and 11].

5. Future Prospects in Computational Biotechnology

Computational biotechnology is a field in rapid transformation, with a large number of breakthrough innovations arising that are poised to redefine many biological and healthcare landscapes. An interesting development is the increasing integration of artificial intelligence (AI) and machine learning (ML) within the process of drug discovery. Therefore, with AI capable of analyzing large datasets, opening up new targets for drugs, and also optimizing the properties of the drugs, this shortens timelines traditionally associated with drug development in an incredible way. Beyond 2020, no less than 20 AI-designed drug candidates were brought to clinical trials-an impressive number, given that conventional drug development takes decades. It allows, therefore, for an *in silico* optimization cycle to be much closer to the real process of making and testing clinical candidates for the best results. Furthermore, synthetic biology has come to lead a revolution in metabolic engineering. Companies are now applying synthetic biology approaches to produce highly valuable phytochemicals through microbial fermentation. This trend would reduce the burden of supply and unveil new scope for sustainable production of nature identical compounds. With all these technologies therefore coming into convergence, it signals that the future for biotechnology responsiveness and alignment to the market demand is not so far. These advances open not only new horizons for drug development but also new promising perspectives in many other healthcare-related and industrial fields.

Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.

References

[1] Barh D, Yiannakopoulou EC, Salawu EO, Bhattacharjee A, Chowbina S, Nalluri JJ, Ghosh P, Azevedo V. In silico disease model: from simple networks to complex diseases. Animal Biotechnology. 2020:441–60.
[2] Bioengineering courses catalog of University of California San Diego, available online: https://catalog.ucsd.edu/courses/BENG.html. Accessed on 29\Nov\2024.
[3] Birmingham Biotechnology Hub". Aug 2023. Available online https://www.eda.gov/sites/default/files/2023-11/Birmingham_Biotechnology_Hub.pdf, Accessed on 1\12\2024.

[4] Chang Y, Hawkins BA, Du JJ, Groundwater PW, Hibbs DE, Lai F. A Guide to In Silico Drug Design. Pharmaceutics. 2022 Dec 23;15(1):49.
[5] Durrant, J.D., McCammon, J.A. Molecular dynamics simulations and drug discovery. BMC Biol 9, 71 (2011).
[6] F. Pun, F. Pulous and P. Alex Zhavoronkov. "Generative Artificial Intelligence for Drug Discovery: How the First AI-Discovered and AI-designed Drug Progressed to Phase 2 Clinical Testing". Mar 2024, available online: https://communities.springernature.com/posts/generative-artificial-intelligence-for-drug-discovery-how-the-first-ai-discovered-and-ai-designed-drug-progressed-to-phase-2-clinical-testing?badge_id=nature-biotechnology. Accessed on 1\Dec\2024.
[7] I.M. Kapetanovic, Computer-aided drug discovery and development (CADDD): In silico-chemico-biological approach,Chemico-Biological Interactions,Volume 171, Issue 2,2008, pp. 165-176.
[8] In Silico Biology" vol. 15, issue 1-2,17 Nov 2023, available online: https://content.iospress.com/journals/in-silico-biology/15/1-2, accessed on 1\Dec\2024.
[9] Michaela Hendling, Ivan Barišić, In-silico Design of DNA Oligonucleotides: Challenges and Approaches, Computational and Structural Biotechnology Journal, Volume 17, 2019, pp. 1056-1065.
[10] Palsson, B.O. The challenges of in silico biology. Nat. Biotechnol. 18, 1147-1150, December 2000.
[11] S. Park, M. Lakshmanan, A. Richelle, Nathan E. Lewis, D. Lee, J. Song, D. Choi, S. Yoon and C. Kontoravdi. "Driving towards digital biomanufacturing by CHO genome-scale models", Trends in Biotechnology: Volume 42, Issue 9, Sep 2024.
[12] Sadybekov, A.V., Katritch, V. Computational approaches streamlining drug discovery. Nature 616, 673–685 (2023).
[13] Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr. Computational methods in drug discovery. Pharmacol Rev. 2013 Dec 31;66(1):334-95.
[14] Tessa Moses, Alain Goossens, Plants for human health: greening biotechnology and synthetic biology, Journal of Experimental Botany, Volume 68, Issue 15, 9 September 2017, Pages 4009–4011.